Cargando…

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants

Detalles Bibliográficos
Autor principal:	Bekeschus, Sander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709854/ https://www.ncbi.nlm.nih.gov/pubmed/34952897 http://dx.doi.org/10.1038/s41392-021-00844-5

Ejemplares similares

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

The dual role of ROS, antioxidants and autophagy in cancer
por: Walton, Emma Louise
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Co-survival of the fittest few: mosaic amplification of receptor tyrosine kinases in glioblastoma
por: Chen, Feng, et al.
Publicado: (2012)

Life and death: the destiny of Phytophthora sojae determined by a receptor-like kinase
por: Wang, He, et al.
Publicado: (2023)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
por: Guo, Renhua, et al.
Publicado: (2011)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation
por: Sorokin, Maxim, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Chen, Qi, et al.
Publicado: (2015)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Li, Xin, et al.
Publicado: (2018)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Regenerative potential of targeting glycogen synthase kinase-3 signaling in neural tissues
por: Jung, Eui-Man, et al.
Publicado: (2015)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
por: Mostazo, Miriam G. Contreras, et al.
Publicado: (2020)

ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?
por: Clemen, Ramona, et al.
Publicado: (2021)

Highlight: Exceptions Are the Rule in Sex Determination
por: McGrath, Casey
Publicado: (2020)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
por: Sierra, J Rafael, et al.
Publicado: (2010)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
por: Bekeschus, Sander, et al.
Publicado: (2021)

‘Fostering critical engagement rather than blind devotion’: calling for transdisciplinary microbiology research
por: Barendse, S. B.
Publicado: (2021)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking
por: Fallahzadeh-Mamaghami, Vahid, et al.
Publicado: (2023)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

Identification of tumor microenvironment‐based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Chen, Wenjie, et al.
Publicado: (2022)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
por: Ohashi, Yoshimi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hmqp9ntpimf5f7pd2947us0ilp